Electronic Quality Management Systems have become central to the way pharmaceutical organisations manage deviations, CAPAs, change controls, audits, training, documentation and other critical quality processes.
Yet the more important an eQMS becomes to an organisation, the more complicated upgrading it can become.
What may appear to be a straightforward software project can quickly become a significant quality and compliance exercise. Migrating records, changing workflows, introducing new functionality or integrating additional platforms can affect validated processes, user permissions, data integrity and regulatory records.
For Quality Assurance teams, the challenge is therefore not simply implementing the newest version of an eQMS. It is doing so without weakening the state of control the system is designed to protect.
Start With Risk, Not With Technology
One of the biggest mistakes organisations can make is treating an eQMS upgrade primarily as an IT project.
Technology teams may lead configuration and implementation, but QA should be involved from the beginning.
ICH Q9(R1) reinforces the importance of quality risk management across pharmaceutical quality systems, while ICH Q10 describes quality risk management and knowledge management as key enablers of an effective Pharmaceutical Quality System.
That principle should shape an eQMS upgrade.
Before implementation begins, organisations should understand:
- Which GxP processes will change?
- Which electronic records could be affected?
- What data will be migrated?
- What integrations exist with other systems?
- Which workflows have the greatest potential impact on product quality or patient safety?
- What could happen if the system or a particular function becomes unavailable?
Not every feature requires the same level of scrutiny. Applying effort proportionate to risk allows QA teams to concentrate resources on functionality that matters most.
Understand What Is Actually Changing
Modern software platforms can receive frequent patches, upgrades and configuration changes. Treating every update as if an entirely new system is being introduced may consume significant resources without adding equivalent quality value.
Instead, organisations should perform a structured impact assessment.
A seemingly minor change could affect an electronic approval workflow, audit trail or automated notification. Conversely, a major user-interface change may have little impact on the system’s underlying GxP functionality.
QA needs visibility of exactly what is changing and why.
This becomes especially important when organisations rely on cloud-based or Software-as-a-Service platforms where vendors may control aspects of the update cycle.
Supplier documentation can support an assessment, but vendor testing should not automatically replace the manufacturer’s responsibility for determining whether the system remains suitable for its intended use.
Move Towards Risk-Based Software Assurance
Regulatory thinking around software assurance continues to evolve.
In February 2026, the FDA issued updated final guidance on Computer Software Assurance for Production and Quality Management System Software in the medical-device environment. The guidance promotes a risk-based approach to establishing confidence that software performs as intended, rather than relying indiscriminately on highly prescriptive testing.
Although organisations must apply the regulations and guidance relevant to their own products and jurisdictions, the broader principle is useful: testing should generate meaningful assurance, not documentation for documentation’s sake.
For an eQMS upgrade, this can mean directing greater testing towards functions such as:
- electronic signatures;
- workflow approvals;
- CAPA management;
- audit trails;
- access controls;
- data transfer;
- interfaces with validated systems;
- report generation; and
- critical automated calculations.
Lower-risk functionality can then be assessed proportionately.
Treat Data Migration as a Quality Process
Data migration is often one of the highest-risk elements of an eQMS upgrade.
Historical deviations, investigations, CAPAs, complaints and change-control records may be required during inspections years after they were created.
QA should therefore establish clear migration rules covering completeness, accuracy, traceability and reconciliation.
Records should not simply arrive in the new system. Organisations need confidence that the correct records arrived, that they remain accessible and readable, and that relationships between records have not been broken.
Audit trails and metadata also require consideration where applicable.
A technically successful migration does not automatically equal a compliant migration.
Protect Business Continuity
Quality processes rarely stop because software is being upgraded.
Deviations still happen. CAPAs still need approval. Employees still require training. Manufacturing changes still need to progress.
An effective upgrade plan therefore requires contingency arrangements.
That might include temporary controlled processes for capturing quality events, clearly defined cutover periods and documented procedures for reconciling any records created while systems are unavailable.
The objective should be to prevent the upgrade itself becoming a source of compliance risk.
Do Not Underestimate Training
Even when functionality improves, users can initially become less effective because familiar workflows have changed.
That creates an overlooked source of quality risk.
A redesigned deviation form, for example, may encourage better investigations long term but initially result in incomplete information if users have not been adequately trained.
Training should therefore go beyond explaining where buttons have moved.
Employees need to understand changes affecting their responsibilities, including revised workflows, escalation routes, data-entry requirements and approval processes.
Post-implementation monitoring can then identify recurring user errors or areas requiring additional support.
The Upgrade Is Not Finished at Go-Live
One of the most valuable stages comes after implementation.
QA teams should monitor system performance, deviations associated with the new platform, support requests, workflow delays and user feedback.
Unexpected patterns may reveal configuration weaknesses that qualification testing did not identify.
This aligns with the broader principle of continual improvement found throughout modern pharmaceutical quality management. FDA’s Quality Management Maturity programme similarly emphasises mature quality practices, proactive improvement and integration between quality, manufacturing and business operations.
QA Can Enable Digital Transformation
Pharmaceutical organisations need modern digital quality systems.
The answer to compliance risk cannot be avoiding change.
Instead, QA needs to help organisations change intelligently.
When upgrades are built around risk management, intended use, robust change control, data integrity and meaningful assurance, companies can introduce new technology without compromising the controls regulators and patients depend upon.
The most mature QA organisations are therefore unlikely to be those that resist digital change. They will be the ones capable of adopting it while maintaining confidence in the quality system throughout the transition.